Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...

NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This ...

There is a simple discount patient access scheme for vadadustat. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact enquiries@medice ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

Tools to help you put the guidance into practice.

Tools to help you put the guidance into practice.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib and venetoclax with or without obinutuzumab within its marketing authorisation for previously untreated chronic ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the vadadustat being ...

The evaluation committee considered evidence submitted by MEDICE, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...